Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Fms‐related receptor tyrosine kinase 3 (FLT3) mutation
acute myeloid leukaemia (AML)
gilteritinib
venetoclax
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
27
03
2024
accepted:
10
05
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
Patients with FLT3-mutated acute myeloid leukaemia (AML) that relapse or are refractory (R/R) to intensive induction have poor outcomes. Gilteritinib has recently become standard-of-care for patients with R/R FLT3-mutated AML. We investigated whether adding venetoclax to gilteritinib (gilt-ven) improves outcomes as compared with gilteritinib monotherapy. We included patients treated with gilteritinib (n = 19) and gilt-ven (n = 17) for R/R AML after intensive chemotherapy. Gilteritinib and gilt-ven groups did not differ in terms of mCRc rates (53% and 65%, p = 0.51) and realization of allogeneic haematopoietic stem-cell transplantation (HSCT, 47% and 35%, p = 0.5). Overall survival (OS) was comparable between groups, although a trend towards better OS was seen with gilt-ven (12-month OS 58.8% [95% CI 39.5%-87.6%]) versus gilteritinib (42.1% [95% CI 24.9%-71.3%] for gilteritinib). Early salvage with gilt-ven versus any other gilteritinib-based approach was associated with the best outcome (p = 0.031). Combination therapy was associated with increased haematological toxicity. In summary, gilt-ven did not improve remissions or HSCT-realization rates in patients with R/R FLT3-mutated AML as compared with gilteritinib and was associated with increased haematological toxicity. Although OS did not differ, a trend towards better survival was suggested with gilt-ven and a survival benefit was shown for gilt-ven approach when sequenced early for salvage.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
Références
Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, et al. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia. 2011;25:939–944.
Pratz KW, Levis M. How I treat FLT3‐mutated AML. Blood. 2017;129:565–571.
Ravandi F, Kantarjian H, Faderl S, Garcia‐Manero G, O'Brien S, Koller C, et al. Outcome of patients with FLT3‐mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34:752–756.
Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Žák P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukaemia (QuANTUM‐First): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2023;401:1571–1583.
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–464.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3‐mutated AML. N Engl J Med. 2019;381:1728–1740.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, et al. Follow‐up of patients with R/R FLT3‐mutation‐positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022;139:3366–3375.
Brinton LT, Zhang P, Williams K, Canfield D, Orwick S, Sher S, et al. Synergistic effect of BCL2 and FLT3 co‐inhibition in acute myeloid leukemia. J Hematol Oncol. 2020;13:139.
Janssen M, Schmidt C, Bruch PM, Blank MF, Rohde C, Waclawiczek A, et al. Venetoclax synergizes with gilteritinib in FLT3 wild‐type high‐risk acute myeloid leukemia by suppressing MCL‐1. Blood. 2022;140:2594–2610.
Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, et al. Inhibition of Bcl‐2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3‐mutated acute myeloid leukemia. Clin Cancer Res. 2019;25:6815–6826.
Perl AE. Improving response to FLT3 inhibitors‐BCL2 the rescue? Clin Cancer Res. 2019;25:6567–6569.
Zhu R, Li L, Nguyen B, Seo J, Wu M, Seale T, et al. FLT3 tyrosine kinase inhibitors synergize with BCL‐2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther. 2021;6:186.
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus Gilteritinib for FLT3‐mutated relapsed/refractory acute myeloid leukemia. J Clin Oncol. 2022;40:4048–4059.
Shimony S, Canaani J, Kugler E, Nachmias B, Ram R, Henig I, et al. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‐world, multi‐center, matched analysis. Ann Hematol. 2022;101:2001–2010.
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–1377.
National Cancer Institute. N.I.o.H., US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0/. Published Jan 3, 2018
Bertoli S, Dumas PY, Bérard E, Largeaud L, Bidet A, Delabesse E, et al. Outcome of relapsed or refractory FLT3‐mutated acute myeloid leukemia before second‐generation FLT3 tyrosine kinase inhibitors: a Toulouse‐Bordeaux DATAML Registry Study. Cancers (Basel). 2020;12(4):773.
Cortes J, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib significantly prolongs overall survival in patients with FLT3‐internal tandem duplication‐mutated (MUT) relapsed/refractory AML in the phase 3, randomized, controlled Quantum‐R trial. 2019 EHA23 (abstr LB2600).
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, et al. Outcomes in patients with FLT3‐mutated relapsed/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of Gilteritinib versus salvage chemotherapy. Transplant Cell Ther. 2023;29:265.e1–265.e210.
Buchrits S, Wolach O. Non‐immunotherapy approaches for relapsed or refractory AML: an update for 2024. Acta Haematol. 2024;147(2):159–174.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3‐mutated AML. J Clin Oncol. 2024;42(13):1499–1508.
Chen N, Pan J, Zhou Y, Mao L, Lou Y, Qian J, et al. Gilteritinib‐based combination therapy in adult relapsed/refractory FLT3‐mutated acute myeloid leukaemia. Br J Haematol. 2024;204(3):861–870.
Ngo D, Tinajero J, Li S, Palmer J, Pourhassan H, Aribi A, et al. Treatment of relapsed or refractory FLT‐3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib. Leuk Lymphoma. 2024;65:1–6.
Perl AE, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, et al. Clinical outcomes in patients with relapsed/refractory FLT3‐mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer J. 2022;12:84.
Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, et al. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022;97:322–328.
Dumas PY, Raffoux E, Bérard E, Bertoli S, Hospital MA, Heiblig M, et al. Gilteritinib activity in refractory or relapsed FLT3‐mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. Leukemia. 2023;37:91–101.